NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,944,174 | -27.5% | 1,774,068 | -7.9% | 0.00% | 0.0% |
| Q2 2023 | $19,238,003 | -3.1% | 1,925,726 | -13.8% | 0.00% | 0.0% |
| Q1 2023 | $19,849,269 | -64.0% | 2,235,278 | -55.4% | 0.00% | -50.0% |
| Q4 2022 | $55,075,394 | +82.8% | 5,015,974 | +116.9% | 0.00% | 0.0% |
| Q3 2022 | $30,128,000 | +12.3% | 2,312,224 | +9.2% | 0.00% | 0.0% |
| Q2 2022 | $26,819,000 | -16.9% | 2,116,771 | -8.1% | 0.00% | 0.0% |
| Q1 2022 | $32,259,000 | -28.5% | 2,302,544 | +47.8% | 0.00% | 0.0% |
| Q4 2021 | $45,096,000 | -7.8% | 1,557,712 | -4.6% | 0.00% | -33.3% |
| Q3 2021 | $48,929,000 | -0.8% | 1,633,131 | -12.2% | 0.00% | 0.0% |
| Q2 2021 | $49,332,000 | +15.2% | 1,859,468 | +35.0% | 0.00% | +50.0% |
| Q1 2021 | $42,838,000 | +188.7% | 1,377,862 | +205.4% | 0.00% | +100.0% |
| Q4 2020 | $14,837,000 | +222.8% | 451,232 | +242.7% | 0.00% | – |
| Q3 2020 | $4,597,000 | – | 131,673 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |